Resmed Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $5.7B+9.9% YoYTTM through 30 Jun 2026
Net Income $1.5B+8.8% YoYTTM through 30 Jun 2026
Free Cash Flow $1.6BTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 61.1% |
| EBITDA Margin | 36.9% |
| Operating Margin | 33.4% |
| Net Margin | 26.9% |
Returns
23.1%ROE
17.0%ROA
27.6%ROIC
Balance Sheet Health
Debt / Equity0.06x
Current Ratio3.10x
Net Debt-$1.1Bnet cash position
Cash & Equivalents$1.5B
Quality Metrics
Altman Z-Score10.92
Piotroski F-Score9 / 9
FCF Margin29.2%
Rule of 4032.0
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2026: $5.7B
Diluted EPS$10.43TTMFY2026: $10.43
Dividend
$1.20Per share, FY20260.54%Yield-5.8%5-yr growth
Capital Allocation
R&D Spend$378.3M
Capex Intensity2.8%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Sleep and Breathing Health Devices | $2.7B | ||
| Masks, Diagnostic Products, and Accessories | $1.9B | ||
| Residential Care Software | $617.6M |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.